Head-to-head · WeighScore
MadeMed vs REMEVi
By GLP-1 ScorecardUpdated
Score comparison
MadeMed has the higher recorded score — 80.4/100 to 73.5/100.
MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | MadeMed | REMEVi |
|---|---|---|
| WeighScore | 80.4/100 | 73.5/100 |
| Grade | B− | C |
| Site position | #23 | #78 |
| Semaglutide | $179 every 30 days; $483/90 days or $1,718/360 days ($143.17 equivalent per 30 days); consultation fees and usable supply require confirmation | $219/mo |
| Tirzepatide | Injection or sublingual: $249 every 30 days; $672/90 days or $2,390/360 days ($199.17 equivalent per 30 days); final fees and supply unverified | $319/mo |
| Coverage | Confirm selected treatment/state: sublingual tirzepatide FAQ lists 40 states; current injection-state map unverified | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #23 · B−
Strengths
- Public selectors show full charges for 30-, 90- and 360-day plans across the listed GLP-1 products
- Advertises the same pricing across doses, ongoing clinical messaging and included injection supplies
- Current terms name MDI Medical Group PC and four partner pharmacy brands
- A 30-day purchase is advertised alongside the larger prepaid options
What to consider
- Lowest advertised equivalents require $1,718/$2,390 360-day billing plans; terms reject prorated refunds
- Product pages list $20/$30 consultation fees while How It Works says consultation is included and ineligible payments are refunded in full
- The forty-state claim is specific to sublingual tirzepatide; an injection-state map was not established
- Assigned clinician/pharmacy branch, patient lab costs, final first debit and usable prescription supply remain unresolved
Site position #78 · C
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
What to consider
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Featured provider
MadeMed
MadeMed scores 80.4/100 (B−). MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.